Part A,Thirty-six Sprague-Dawley epileptic rats were allocated into 6 groups(Al,A2,A3,A4,A5,A6), group A1, control; in other groups, the rats were given oxytocin Ing (group A2), oxytocin 10ng (group A3), oxytocin 100ng (group A4), oxytocin receptor antagonist [d(CH2)s-OVT] 1μg (group A5),[d(CH2)5-OVT]1μg+ oxytocin 100ng (group A6), into lateral cerebroventr.

Advances on leukotrienes and leukotriene receptor antagonists in asthma;

Eplerenone——a new aldosterone receptor antagonist with cardiovascular protective effect;

Anti-asthmatic effects of interleukin-1 receptor antagonist in sensitized guinea pigs;

Study on the quantitative structure-activity relationship of nonpeptide endothelin receptor antagonist: Bis-sulfonamides;

Effects of ETP-508,a novel endothelin receptor antagonist,on the proliferation of pulmonary arterial smooth muscle cells of rat cultured in hypoxia environment;

Therapic effects of CPU0213,a novel endothelin receptor antagonist,on isopreterenol induced cardiomyopathy;

For a series of phenoxyalkylamines 1-adrenocepter antagonist (DDPH and its analogues), a three- dimensional quantitative-structure activity relationship (3D-QSAR) model is established by using the compa- rative molecular field analysis (CoMFA), with the cross-checking and noncross-checking regression coeffi- cients, q2 and r2, of 0.

Effects of endothelin receptor antagonists on portal hypertension and ET-1 mRNA expression in cirrhotic portal hypertensive rat;